Abstract Total hip arthroplasty is an effective surgery to treat osteoarthritis. Given the rising demand for a higher quality of life, this procedure is being performed on increasingly younger patients. However, a longer life expectancy is also tied to a higher demand for multiple revision surgeries for the same patient. This poses technical challenges due to bone loss. There is a growing need to identify durable and highly functional implants that are suitable for future revision. Although cemented femoral stems were the main option in the past, uncemented femoral stems have demonstrated long-term fixation and excellent results. However, some issues related to fixation can still be improved. Short femoral stems have been developed to address some of these challenges while maintaining the good results obtained with conventional stems. This study analyzes the experience after 10 years of using short femoral stems in hip surgeries on young patients. Biomechanical outcomes and femoral bone preservation are compared, postoperative outcomes regarding return to sports are reported, and complications related to their use are evaluated. Short stems have multiple advantages when used in primary hip surgery. The indication for this type of implant is justified in young and active patients, to reproduce the results of conventional implants with less bone consumption and the possibility of future revision.

Resumen La artroplastia total de cadera es una cirugía eficaz para tratar la artrosis. Con el aumento de la necesidad de una mejor calidad de vida, este procedimiento se está realizando en pacientes más jóvenes. Pero, con la mayor expectativa de vida, también crece la demanda de múltiples cirugías de revisión para el mismo paciente. Esto plantea desafíos técnicos debido a la pérdida de hueso. Existe una necesidad creciente de identificar implantes duraderos y altamente funcionales que sean adecuados para la revisión futura. Aunque los vastagos femorales cementados eran la opción principal en el pasado, los vastagos femorales no cementados han logrado una fijación a largo plazo y excelentes resultados. Sin embargo, aún se pueden mejorar algunos problemas relacionados con la fijación. Los vastagos femorales cortos han sido desarrollados para abordar algunos de estos desafíos, mientras se mantienen los buenos resultados obtenidos con los vastagos convencionales. En este artículo, se analiza la experiencia tras 10 años de uso de vastagos femorales cortos en cirugías de cadera en pacientes jóvenes. Se comparan los resultados biomecánicos y la preservación ósea femoral, se reportan los resultados posoperatorios en relación con el regreso al deporte, y se evalúan las complicaciones relacionadas con su uso. El empleo de vástagos cortos en cirugía primaria de cadera brinda múltiples ventajas. La indicación de este tipo de implante está justificada en pacientes jóvenes y activos, con el objetivo de reproducir los resultados de los implantes convencionales con un menor consumo de hueso y la posibilidad de una revisión futura.

Resumen Introducción: El objetivo de este estudio fue analizar los resultados clínicos, radiográficos y funcionales en pacientes <20 años sometidos a artroplastia total de cadera con vástago femoral tipo 2B corto no cementado. Materiales y Métodos: Se realizó un estudio retrospectivo de 13 pacientes (16 artroplastias totales de cadera) operados entre enero de 2006 y enero de 2021. La edad media y el índice de masa corporal eran de 16.5 ± 2.5 años y 22,74 ± 4,06 kg/m2, respectivamente. El seguimiento medio fue de 43.3 meses (rango 12-128, DE ± 33.45). Se analizaron las indicaciones quirúrgicas, y los resultados funcionales y radiográficos. La supervivencia del implante se calculó con la estimación de Kaplan-Meier. Resultados: La indicación predominante fue necrosis avascular (9/16 caderas [56%]), el 66% estaba asociada al uso prolongado de corticoides. El HHS para cadera mejoró significativamente de 33 ± 16,5 a 94 ± 5,6 (p <0,001). Diez (76%) pacientes usaban dispositivos de asistencia para caminar antes de la artroplastia, pero ninguno los necesitaba al final del seguimiento. Se observó radiolucidez en un componente acetabular sin repercusión clínica hasta el final del seguimiento. No se registraron signos radiográficos de aflojamiento del componente femoral. La supervivencia del implante fue del 100% hasta el final del seguimiento. Conclusiones: La artroplastia total de cadera primaria con un vástago femoral corto no cementado en pacientes <20 años con artrosis avanzada de cadera logró resultados equiparables a los ya publicados, con la particularidad de que es un procedimiento menos invasivo y ahorra capital óseo femoral.

Abstract Introduction: To our knowledge, there is no published literature on the outcomes of short-stem total hip arthroplasty (THA) in patients under 20 years old. This study aimed to analyze clinical, radiological, and functional outcomes in patients under 20 years of age undergoing THA with a short uncemented 2B femoral stem. Materials and Methods: We carried out a retrospective study of 13 patients (16 THAs) treated between January 2006 and January 2021. The mean age and BMI were 16.5±2.5 years and 22.74±4.06 kg/m2, respectively. The mean follow-up was 43.3 months (range 12-128, SD ± 33.45). Surgical indications, as well as functional and radiologic outcomes, were analyzed. Implant survival was calculated with the Kaplan-Meier estimate. Results: The predominant indication was avascular necrosis (9/16 hips [56%]), of which 66% were associated with prolonged use of corticosteroids. Eight (50%) of the cases had undergone surgeries before the THA. The Harris hip score improved significantly from 33±16.5 to 94±5.6 (p<0.001). Ten (76%) patients required assistive devices to walk preoperatively, and no patient required them at the end of follow-up. Radiolucency was evident in one acetabular component, without clinical implications. There were no signs of femoral component loosening. The implant survival was 100% at the last follow-up. Conclusions: Short stems in primary THAs in patients under 20 years of age with advanced hip osteoarthritis showed clinical, functional, and radiological outcomes comparable to those previously reported in the literature for conventional stems, with the particularity of being less invasive and sparing femoral bone stock.

Local anesthetic efficacy of tramadol has been reported following intradermal application. Our aim was to investigate the effect of perineural tramadol as the sole analgesic in two pain models. Male Wistar rats (280-380 g; N = 5/group) were used in these experiments. A neurostimulation-guided sciatic nerve block was performed and 2% lidocaine or tramadol (1.25 and 5 mg) was perineurally injected in two different animal pain models. In the flinching behavior test, the number of flinches was evaluated and in the plantar incision model, mechanical and heat thresholds were measured. Motor effects of lidocaine and tramadol were quantified and a motor block score elaborated. Tramadol, 1.25 mg, completely blocked the first and reduced the second phase of the flinching behavior test. In the plantar incision model, tramadol (1.25 mg) increased both paw withdrawal latency in response to radiant heat (8.3 ± 1.1, 12.7 ± 1.8, 8.4 ± 0.8, and 11.1 ± 3.3 s) and mechanical threshold in response to von Frey filaments (459 ± 82.8, 447.5 ± 91.7, 320.1 ± 120, 126.43 ± 92.8 mN) at 5, 15, 30, and 60 min, respectively. Sham block or contralateral sciatic nerve block did not differ from perineural saline injection throughout the study in either model. The effect of tramadol was not antagonized by intraperitoneal naloxone. High dose tramadol (5 mg) blocked motor function as well as 2% lidocaine. In conclusion, tramadol blocks nociception and motor function in vivo similar to local anesthetics.